ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study

Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall. Bristol Myers Squibb may have gone big in its pursuit of cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources…

Source: FierceBiotech